Immunosuppression regimen and latitude impact keratinocyte carcinoma risk in US liver transplant recipients

被引:0
|
作者
Rosenthal, Benjamin E. [1 ]
Schaubel, Douglas E. [2 ]
Lewis, James D. [2 ,3 ]
Margolis, David J. [2 ,4 ]
Goldberg, David S. [5 ]
Bittermann, Therese [2 ,3 ,6 ]
机构
[1] Univ Penn, Dept Med, Philadelphia, PA USA
[2] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA USA
[5] Univ Miami, Dept Med, Miller Sch Med, Div Digest Hlth & Liver Dis, Miami, FL USA
[6] Hosp Univ Penn, Penn Transplant Inst, Dulles 2, 3400 Spruce St, Philadelphia, PA 19104 USA
关键词
Liver transplantation; Immunosuppression; Latitude; Keratinocyte carcinoma; NONMELANOMA SKIN-CANCER; SQUAMOUS-CELL CARCINOMA; KIDNEY; ASSOCIATION; POPULATION; QUEENSLAND; MANAGEMENT; INHIBITORS;
D O I
10.1007/s00403-024-03404-3
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Immunosuppression after solid organ transplantation is associated with an increased risk of keratinocyte carcinoma (KC). Despite its established morbidity, KC risk in liver transplant (LT) recipients is understudied, including the contribution of immunosuppression regimen and latitude. A retrospective cohort of 9,966 adult first LT alone recipients alive with their native allograft at 1-year post-LT without prior KC between 2007 and 2016 were identified using linked data from the Organ Procurement and Transplantation Network and Medicare administrative claims. The primary exposures were immunosuppression regimen and latitude of residence. The primary outcome was incident, de novo KC occurring at least 1-year after LT. Adjusted Cox regression analysis stratified by transplant center was used in all analyses. The cohort was 63.4% male, 70.2% White and with median age 61 years (interquartile range, IQR, 54-66) at transplant. Calcineurin inhibitor (CNI) with anti-metabolite combination was independently associated with incident KC when measured as intention-to-treat (adjusted hazard ratio (aHR) 1.21 vs. CNI monotherapy, 95% CI 1.02-1.43, p = 0.026), in a time-updating as-treated analysis (aHR 1.61, 95% CI 1.34-1.93; p < 0.001) and when measured as cumulative exposure (aHR 1.13 per 6-month increase, 95% CI: 1.02-1.33; p = 0.027). More southern latitude of residence was also independently associated with incident KC with an aHR of 1.26 per 5 degrees N decrease towards the Equator (95% CI: 1.08-1.47, p = 0.003). We demonstrate independent effects of CNI with antiM immunosuppression regimen and latitude of residence on the risk of post-LT KC, which will better inform screening practices and immunosuppression management.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Options for Induction Immunosuppression in Liver Transplant Recipients
    Michael A. J. Moser
    Drugs, 2002, 62 : 995 - 1011
  • [22] Immunosuppression in liver transplant recipients with renal impairment
    Duvoux, C.
    Pageaux, G. P.
    JOURNAL OF HEPATOLOGY, 2011, 54 (05) : 1041 - 1054
  • [23] Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus
    Levitsky, Josh
    Mathew, James M.
    Miller, Joshua
    Heinrichs, Jessica
    Huang, Xumei
    Abecassis, Michael M.
    HEPATOLOGY, 2016, 64 : 1A - 1A
  • [24] Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus
    Levitsky, Josh
    Burrell, Bryna E.
    Kanaparthi, Sai
    Turka, Laurence A.
    Kurian, Sunil
    Sanchez-Fueyo, Alberto
    Lozano, Juan J.
    Demetris, Anthony
    Lesniak, Andrew
    Kirk, Allan D.
    Stempora, Linda
    Yang, Guang-Yu
    Mathew, James M.
    HEPATOLOGY, 2020, 72 (02) : 569 - 583
  • [25] Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients
    Boucher, A
    Masse, M
    Lauzon, L
    Morin, M
    Dandavino, R
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1799 - 1802
  • [26] Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients.
    Locke, J.
    James, N.
    Mehta, S.
    Pappas, P.
    Mannon, R.
    Desai, N.
    Montgomery, R.
    Segev, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 84 - 84
  • [27] IMPACT OF SIROLIMUS BASED IMMUNOSUPPRESSION ON FIBROSIS PROGRESSION IN HCV LIVER TRANSPLANT RECIPIENTS
    Nandy, Nina
    Rogers, Christin
    Nasser, Imad
    Challies, Tracy L.
    Karp, Seth
    Johnson, Scott
    Hanto, Douglas W.
    Curry, Michael P.
    HEPATOLOGY, 2010, 52 (04) : 395A - 395A
  • [28] Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients
    Nogueras Lopez, Flor
    Abellan Alfocea, Patricia
    Ortega Suazo, Eva Julissa
    Lopez Garrido, Maria Angeles
    Becerra Massare, Antonio
    Gila Medina, Ana Maria
    Redondo Cerezo, Eduardo
    Espinosa Aguilar, M. Dolores
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (02) : 556 - 558
  • [29] Declining incidence of keratinocyte carcinoma in organ transplant recipients
    Menzies, S.
    O'Leary, E.
    Callaghan, G.
    Galligan, M.
    Deady, S.
    Gadallah, B.
    Lenane, P.
    Lally, A.
    Houlihan, D. D.
    Morris, P. G.
    Sexton, D. J.
    McCormick, P. A.
    Egan, J. J.
    O'Neill, J. P.
    Conlon, P. J.
    Moloney, F. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) : 983 - 991
  • [30] Evaluation of the impact of an oral cytomegalovirus prophylaxis regimen in liver transplant recipients.
    Quan, DJ
    Hirata, J
    PHARMACOTHERAPY, 2003, 23 (10): : 1365 - 1365